Get started
BRISTOL-MYERS SQUIBB COBRISTOL-MYERS SQUIBB COBRISTOL-MYERS SQUIBB CO

BRISTOL-MYERS SQUIBB CO

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

BMYS chart


Full chart

Key facts today

Bristol Myers Squibb's Opdivo (nivolumab) is positioned as a competitor to Summit Therapeutics' ivonescimab, which is currently undergoing clinical trials for non-small cell lung cancer.
Analyze the impactAnalyze the impact

BMYS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪101.69 B‬ EUR
Dividend yield (indicated)
4.42%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.23 EUR
Net income (FY)
‪7.27 B‬ EUR
Revenue (FY)
‪40.78 B‬ EUR
Shares float
‪2.03 B‬
Beta (1Y)
0.00

Employees


Employees (FY)
‪34.1 K‬
Change (1Y)
−200 −0.58%
Revenue / Employee (1Y)
‪1.32 M‬ EUR
Net income / Employee (1Y)
‪235.34 K‬ EUR

About Bristol-Myers Squibb Company


Sector
Health Technology
CEO
Christopher S. Boerner
Headquarters
Princeton
Website
bms.com
Founded
1933
FIGI
BBG00PKLKB53
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

BMYS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BMYS highest yielding bonds


C
BMY4036425
Celgene Corporation 5.25% 15-AUG-2043
Yield to maturity
6.45%
Maturity date
Aug 15, 2043
BMY.GC
Bristol-Myers Squibb Company 6.875% 01-AUG-2097
Yield to maturity
6.02%
Maturity date
Aug 1, 2097
C
BMY4275603
Celgene Corporation 5.0% 15-AUG-2045
Yield to maturity
5.94%
Maturity date
Aug 15, 2045
C
BMY3685700
Celgene Corporation 5.7% 15-OCT-2040
Yield to maturity
5.92%
Maturity date
Oct 15, 2040
C
BMY4560589
Celgene Corporation 4.35% 15-NOV-2047
Yield to maturity
5.89%
Maturity date
Nov 15, 2047
US110122EC8
BRIST.MYERS 23/63
Yield to maturity
5.80%
Maturity date
Nov 15, 2063
C
BMY4597874
Celgene Corporation 4.55% 20-FEB-2048
Yield to maturity
5.67%
Maturity date
Feb 20, 2048
US110122EB0
BRIST.MYERS 23/53
Yield to maturity
5.63%
Maturity date
Nov 15, 2053
US110122EL8
BRIST.MYERS 24/64
Yield to maturity
5.63%
Maturity date
Feb 22, 2064
US110122EK0
BRIST.MYERS 24/54
Yield to maturity
5.52%
Maturity date
Feb 22, 2054
BMY5007348
Bristol-Myers Squibb Company 5.7% 15-OCT-2040
Yield to maturity
5.43%
Maturity date
Oct 15, 2040

Explore more bonds 

Sparks


Curated watchlists where BMYS is featured.

See all sparks 

Frequently Asked Questions


The current price of BMYS is 50.80 EUR — it has increased by 0.22% in the past 24 hours. Watch BRISTOL-MYERS SQUIBB CO stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange BRISTOL-MYERS SQUIBB CO stocks are traded under the ticker BMYS.
BMYS stock has risen by 5.27% compared to the previous week, the month change is a 3.40% rise, over the last year BRISTOL-MYERS SQUIBB CO has showed a 3.15% increase.
We've gathered analysts' opinions on BRISTOL-MYERS SQUIBB CO future price: according to them, BMYS price has a max estimate of 59.07 EUR and a min estimate of 33.23 EUR. Watch BMYS chart and read a more detailed BRISTOL-MYERS SQUIBB CO stock forecast: see what analysts think of BRISTOL-MYERS SQUIBB CO and suggest that you do with its stocks.
BMYS reached its all-time high on Nov 9, 2022 with the price of 80.73 EUR, and its all-time low was 36.42 EUR and was reached on Jul 5, 2024. View more price dynamics on BMYS chart.
See other stocks reaching their highest and lowest prices.
BMYS stock is 0.59% volatile and has beta coefficient of 0.00. Track BRISTOL-MYERS SQUIBB CO stock price on the chart and check out the list of the most volatile stocks — is BRISTOL-MYERS SQUIBB CO there?
Today BRISTOL-MYERS SQUIBB CO has the market capitalization of ‪103.41 B‬, it has decreased by −0.77% over the last week.
Yes, you can track BRISTOL-MYERS SQUIBB CO financials in yearly and quarterly reports right on TradingView.
BRISTOL-MYERS SQUIBB CO is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
BMYS earnings for the last quarter are 1.62 EUR per share, whereas the estimation was 1.34 EUR resulting in a 20.47% surprise. The estimated earnings for the next quarter are 1.36 EUR per share. See more details about BRISTOL-MYERS SQUIBB CO earnings.
BRISTOL-MYERS SQUIBB CO revenue for the last quarter amounts to ‪10.68 B‬ EUR, despite the estimated figure of ‪10.12 B‬ EUR. In the next quarter, revenue is expected to reach ‪10.61 B‬ EUR.
BMYS net income for the last quarter is ‪1.09 B‬ EUR, while the quarter before that showed ‪1.57 B‬ EUR of net income which accounts for −30.65% change. Track more BRISTOL-MYERS SQUIBB CO financial stats to get the full picture.
Yes, BMYS dividends are paid quarterly. The last dividend per share was 0.55 EUR. As of today, Dividend Yield (TTM)% is 4.33%. Tracking BRISTOL-MYERS SQUIBB CO dividends might help you take more informed decisions.
BRISTOL-MYERS SQUIBB CO dividend yield was 4.50% in 2023, and payout ratio reached 59.82%. The year before the numbers were 3.04% and 74.28% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 5, 2024, the company has ‪34.10 K‬ employees. See our rating of the largest employees — is BRISTOL-MYERS SQUIBB CO on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BRISTOL-MYERS SQUIBB CO EBITDA is ‪16.62 B‬ EUR, and current EBITDA margin is 40.62%. See more stats in BRISTOL-MYERS SQUIBB CO financial statements.
Like other stocks, BMYS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BRISTOL-MYERS SQUIBB CO stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BRISTOL-MYERS SQUIBB CO technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BRISTOL-MYERS SQUIBB CO stock shows the buy signal. See more of BRISTOL-MYERS SQUIBB CO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.